drugset
drugset / Trial / NCT05121441

Study to Evaluate ARD-101 in Adults With Obesity

NCT05121441 ↗

Phase 2 Completed 20 enrolled Aardvark Therapeutics, Inc. University of California, San Diego · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to evaluate safety and efficacy of twice-daily ARD-101 in obese subjects with a body mass index (BMI) of 30-45 kg/m2.

Timeline

Start
2021-11-15
Primary completion
2022-11-09
Completion
2022-11-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject ARD-101 Small molecule 200 mg Oral

Indications

obesity disorder